Literature DB >> 23600367

An observational cross-sectional survey of rosacea: clinical associations and progression between subtypes.

J Tan1, U Blume-Peytavi, J P Ortonne, K Wilhelm, L Marticou, E Baltas, M Rivier, L Petit, P Martel.   

Abstract

BACKGROUND: Few studies have evaluated differences between rosacea subtypes in epidemiological associations and clinical features. The natural history of rosacea is unknown and progression between subtypes has been implied but not formally evaluated.
OBJECTIVES: To assess associations between the four rosacea subtypes [erythematotelangiectatic (ETR), papulopustular (PPR), phymatous (PHY) and ocular], including quantitative and qualitative details on primary and secondary features of rosacea. A secondary objective was to evaluate for the potential of progression between subtypes.
METHODS: This cross-sectional study recruited subjects with rosacea from Northern Germany and comprised clinical evaluation by a dermatologist and a survey of demographics and onset of rosacea-associated signs and symptoms.
RESULTS: A total of 135 subjects with rosacea were enrolled. PHY was more frequently associated with PPR than ETR (P < 0·001). Compared with ETR, PPR was significantly associated with facial burning/stinging (P = 0·001), phymas (P < 0·001) and oedema (P < 0·001); and during flushing episodes, was more frequently associated with burning (P = 0·018), skin tension (P = 0·005) and itching (P = 0·027). ETR was more frequently associated with dry facial skin (P < 0·001). Flushing was reported by 66% and the site most frequently involved was the cheeks (100%). Papulopustules were evanescent in 42% and the sites most frequently involved were the cheeks (80%) and nose (67%). Of those fulfilling criteria for at least two subtypes, 66% developed ETR before PPR; 92% developed ETR before PHY; 83% developed PPR before PHY; and the majority developed cutaneous rosacea-associated features before ocular signs/symptoms.
CONCLUSIONS: Significant differences exist between ETR and PPR in rosacea-associated features and in subtype associations. A small proportion of subjects with rosacea may progress between subtypes.
© 2013 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2013        PMID: 23600367     DOI: 10.1111/bjd.12385

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  20 in total

1.  Rosacea, Use of Tetracycline, and Risk of Incident Inflammatory Bowel Disease in Women.

Authors:  Wen-Qing Li; Eunyoung Cho; Hamed Khalili; Shaowei Wu; Andrew T Chan; Abrar A Qureshi
Journal:  Clin Gastroenterol Hepatol       Date:  2015-09-25       Impact factor: 11.382

Review 2.  Skin barrier in rosacea.

Authors:  Flavia Alvim Sant'Anna Addor
Journal:  An Bras Dermatol       Date:  2016 Jan-Feb       Impact factor: 1.896

3.  Cigarette Smoking and Risk of Incident Rosacea in Women.

Authors:  Suyun Li; Eunyoung Cho; Aaron M Drucker; Abrar A Qureshi; Wen-Qing Li
Journal:  Am J Epidemiol       Date:  2017-07-01       Impact factor: 4.897

4.  Alcohol intake and risk of rosacea in US women.

Authors:  Suyun Li; Eunyoung Cho; Aaron M Drucker; Abrar A Qureshi; Wen-Qing Li
Journal:  J Am Acad Dermatol       Date:  2017-04-20       Impact factor: 11.527

Review 5.  Interventions for rosacea.

Authors:  Esther J van Zuuren; Zbys Fedorowicz; Ben Carter; Mireille M D van der Linden; Lyn Charland
Journal:  Cochrane Database Syst Rev       Date:  2015-04-28

Review 6.  Improving Treatment of Erythematotelangiectatic Rosacea with Laser and/or Topical Therapy Through Enhanced Discrimination of its Clinical Features.

Authors:  Giuseppe Micali; Peter Arne Gerber; Francesco Lacarrubba; Gregor Schäfer
Journal:  J Clin Aesthet Dermatol       Date:  2016-07-01

Review 7.  Cutaneous and ocular rosacea: Common and specific physiopathogenic mechanisms and study models.

Authors:  Daniela Rodrigues-Braz; Min Zhao; Nilufer Yesilirmak; Selim Aractingi; Francine Behar-Cohen; Jean-Louis Bourges
Journal:  Mol Vis       Date:  2021-05-13       Impact factor: 2.367

8.  The Role of Topical Brimonidine Tartrate Gel as a Novel Therapeutic Option for Persistent Facial Erythema Associated with Rosacea.

Authors:  Andrew William Johnson; Sandra Marchese Johnson
Journal:  Dermatol Ther (Heidelb)       Date:  2015-06-26

Review 9.  Major pathophysiological correlations of rosacea: a complete clinical appraisal.

Authors:  Ravi Chandra Vemuri; Rohit Gundamaraju; Shamala Devi Sekaran; Rishya Manikam
Journal:  Int J Med Sci       Date:  2015-05-05       Impact factor: 3.738

Review 10.  The role of brimonidine tartrate gel in the treatment of rosacea.

Authors:  J Mark Jackson; Melissa Knuckles; John Paul Minni; Sandra Marchese Johnson; Kevin Tate Belasco
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.